The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
The landscape of hepatobiliary adverse reactions across 53 herbal and dietary supplements reveals immune-mediated injury as a common cause of hepatitis
Abstract
Recent evidence suggests herbal-induced liver injury (HILI) to account for 20% of cases among the U.S. Drug-Induced-Liver-Injury-Network. To define injury patterns of HILI, we reviewed the clinical data of 413 patients exposed to 53 HDS products by considering the evidence for HILI and its grades of severity. Outstandingly, females developed HILI more rapidly (p = 0.018) and the time to recovery was significantly increased (p = 0.0153). > 90% of reported cases were severe and half of HDS products caused acute liver failure (ALF) requiring liver transplantation or resulted in fatal outcomes. Liver biopsies of 243 patients defined 13 histological features; two-thirds of products elicited immune-mediated hepatitis and included 154 Hy's law positive cases. The histological injury patterns were confirmed among unrelated patients, while accidental re-challenges evidenced culprits as causative. Furthermore, one-fifth of patients presented elevated autoantibody titres indicative of autoimmune-like HILI, and one-third of the products were linked to chronic hepatitis and cholestatic injuries not resolving within 6 months. Lastly, INR and TBL are critical laboratory parameters to predict progression of severe HILI to ALF. Our study highlights the need for a regulatory framework to minimize the risk for HILI. Better education of the public and a physician-supervised self-medication plan will be important measures to abate risk of HILI.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“used the method of the Drug-Induced Liver Injury Network (DILIN)67 for causality assessment, which comes along without any specific element scoring and provides only arbitrary causality gradings as percentage ranges;68”
From Herb-induced Liver Injury in Asia and Current Role of RUCAM for Causality Assessment in 11,160 Published Cases (2020) · cites this paper as [67]
In the citing paper
“additionally, other CAMs were used,67 known for being not specific for liver injury cases and not based on typical, individually scored liver-related key elements, as amply discussed previously15 and reiterated recently.68”
From Herb-induced Liver Injury in Asia and Current Role of RUCAM for Causality Assessment in 11,160 Published Cases (2020) · cites this paper as [67]
In the citing paper
“Critical is also the data source of used cases, which were partially retrieved from the USA’s National Institutes of Health LiverTox database,67 known for inclusion of liver injury cases lacking robust CAMs and being therefore disputed.69–71”
From Herb-induced Liver Injury in Asia and Current Role of RUCAM for Causality Assessment in 11,160 Published Cases (2020) · cites this paper as [67]
In the citing paper
“In contrast, cases presented by the second group of the USA FDA67 were partially assessed using the updated RUCAM15 or a unique, not validated evidence-based method.”
From Herb-induced Liver Injury in Asia and Current Role of RUCAM for Causality Assessment in 11,160 Published Cases (2020) · cites this paper as [67]
In the citing paper
“Generally problematic are reports presented as network data when case presentations and causality assessments are poor.67,96,100”
From Herb-induced Liver Injury in Asia and Current Role of RUCAM for Causality Assessment in 11,160 Published Cases (2020) · cites this paper as [67]
In the citing paper
“Cases were also derived from the LiverTox database,67 with its published problems in assessing a correct causality in liver injury cases.69–71”
From Herb-induced Liver Injury in Asia and Current Role of RUCAM for Causality Assessment in 11,160 Published Cases (2020) · cites this paper as [67]
In the citing paper
“From outside of Asia, reports were published by authors of the USA on a few cases of HILI by TCMs.3,67”
From Herb-induced Liver Injury in Asia and Current Role of RUCAM for Causality Assessment in 11,160 Published Cases (2020) · cites this paper as [67]
Citations
Cites
Ekor, M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00177 · Cited by 3,919
Incidence and Etiology of Drug-Induced Liver Injury in Mainland China
Shen, T., Liu, Y., Shang, J., Xie, Q., Li, J., Yan, M., Xu, J., Niu, J., Liu, J., Watkins, P. B., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.002 · Cited by 615
Chen, M., Suzuki, A., Thakkar, S., Yu, K., Hu, C., & Tong, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.015 · Cited by 398
Self-citation
Research works printed but not linked: 25
- Bailey RL, Gahche JJ, Lentino CV et al (2010) Dietary supplement use in the United States, 2003–2006. J Nutr 110:133025
- Bjornsson E, Talwalkar J, Treeprasertsuk S et al (2010) Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 51(6):2040–2048. https://doi.org/10.1002/hep.23588 · DOI · Paper page
- Bjornsson ES, Bergmann O, Jonasson JG, Grondal G, Gudbjornsson B, Olafsson S (2017) Drug-induced autoimmune hepatitis: response to corticosteroids and lack of relapse after cessation of steroids. Clin Gastroenterol Hepatol 15(10):1635–1636. https://doi.org/10.1016/j.cgh.2017.05.027 · DOI · Paper page
- Burt AD, MacSween RN (1993) Bile duct proliferation–its true significance? Histopathology 23(6):599–602 · DOI
- Castiella A, Zapata E, Lucena MI, Andrade RJ (2014) Drug-induced autoimmune liver disease: a diagnostic dilemma of an increasingly reported disease. World J Hepatol 6(4):160–168. https://doi.org/10.4254/wjh.v6.i4.160 · DOI · Paper page
- Chalasani N, Fontana RJ, Bonkovsky HL et al (2008) Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 135(6):1924–1934. https://doi.org/10.1053/j.gastro.2008.09.011(e1–4) · DOI · Paper page
- Chalasani NP, Hayashi PH, Bonkovsky HL et al (2014) ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 109(7):950–966. https://doi.org/10.1038/ajg.2014.131(quiz 967) · DOI · Paper page
- Chalasani N, Bonkovsky HL, Fontana R et al (2015) Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 148(7):1340–1352.e7 · DOI · Paper page
- Danan G, Teschke R (2019) Roussel Uclaf causality assessment method for drug-induced liver injury: present and future. Front Pharmacol 10:853. https://doi.org/10.3389/fphar.2019.00853 · DOI · Paper page
- Devarbhavi H, Bjornsson ES (2019) RE: incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology. https://doi.org/10.1053/j.gastro.2019.06.045 · DOI · Paper page
- Frazier TH, Krueger KJ (2009) Hepatotoxic herbs: will injury mechanisms guide treatment strategies? Curr Gastroenterol Rep 11(4):317–324 · DOI
- Goldberg DS, Forde KA, Carbonari DM et al (2015) Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. Gastroenterology 148(7):1353–1361.e3 · DOI
- Gomes ER, Demoly P (2005) Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 5(4):309–316 · DOI
- Kosters A, Karpen SJ (2010) The role of inflammation in cholestasis: clinical and basic aspects. Semin Liver Dis 30(2):186–194. https://doi.org/10.1055/s-0030-1253227 · DOI
- Navarro VJ, Lucena MI (2014) Hepatotoxicity induced by herbal and dietary supplements. Semin Liver Dis 34(2):172–193. https://doi.org/10.1055/s-0034-1375958 · DOI
- Navarro VJ, Khan I, Bjornsson E, Seeff LB, Serrano J, Hoofnagle JH (2017) Liver injury from herbal and dietary supplements. Hepatology 65(1):363–373. https://doi.org/10.1002/hep.28813 · DOI
- Navarro V, Avula B, Khan I et al (2019) The contents of herbal and dietary supplements implicated in liver injury in the United States are frequently mislabeled. Hepatol Commun 3(6):792–794. https://doi.org/10.1002/hep4.1346 · DOI · Paper page
- Philips CA, Paramaguru R, Joy AK, Antony KL, Augustine P (2018) Clinical outcomes, histopathological patterns, and chemical analysis of Ayurveda and herbal medicine associated with severe liver injury—a single-center experience from southern India. Indian J Gastroenterol 37(1):9–17. https://doi.org/10.1007/s12664-017-0815-8 · DOI · Paper page
- Real M, Barnhill MS, Higley C, Rosenberg J, Lewis JH (2019) Drug-induced liver injury: highlights of the recent literature. Drug Saf 42(3):365–387. https://doi.org/10.1007/s40264-018-0743-2 · DOI · Paper page
- Stickel F, Shouval D (2015) Hepatotoxicity of herbal and dietary supplements: an update. Arch Toxicol 89(6):851–865. https://doi.org/10.1007/s00204-015-1471-3 · DOI
- Teschke R (2019) Idiosyncratic DILI: analysis of 46,266 cases assessed for causality by RUCAM and published from 2014 to early 2019. Front Pharmacol 10:730. https://doi.org/10.3389/fphar.2019.00730 · DOI · Paper page
- Teschke R, Eickhoff A (2017) Suspected liver injury and the dilemma of causality. Dig Dis Sci 62(4):1095–1098. https://doi.org/10.1007/s10620-016-4442-5 · DOI
- Trauner M, Fickert P, Stauber RE (1999) Inflammation-induced cholestasis. J Gastroenterol Hepatol 14(10):946–959 · DOI
- Verdonk RC, Lozano MF, van den Berg AP, Gouw AS (2016) Bile ductal injury and ductular reaction are frequent phenomena with different significance in autoimmune hepatitis. Liver Int 36(9):1362–1369. https://doi.org/10.1111/liv.13083 · DOI
- Wlodzimirow KA, Eslami S, Abu-Hanna A, Nieuwoudt M, Chamuleau RA (2012) Systematic review: acute liver failure - one disease, more than 40 definitions. Aliment Pharmacol Ther 35(11):1245–1256. https://doi.org/10.1111/j.1365-2036.2012.05097.x · DOI
Cited by
Sorted by citations
Teschke, R., Zhu, Y., & Jing, J. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00009 · Cited by 41
Metadata
- Authors
- Zhu, J., Chen, M., Borlak, J., & Tong, W.
- ORCID
- Borlak, Jürgen
- Venue
- Archives of Toxicology
- Published
- 2019-11-13
- Volume
- 94
- Issue
- 1
- Pages
- 273-293
- ISSN
- 0340-5761
- 1432-0738
- Cited by
- 18
- References
- 3
- Language
- en
- Funders
- FDA Office of Women’s Health
- ORISE Research Participation Program at the National Center for Toxicological Research, U.S. FDA
- US Food and Drug Administration's National Center for Toxicological Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
